

# TMEM143 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP16484c

## **Specification**

# TMEM143 Antibody (Center) Blocking Peptide - Product Information

**Primary Accession** 

**Q96AN5** 

# TMEM143 Antibody (Center) Blocking Peptide - Additional Information

**Gene ID 55260** 

#### **Other Names**

Transmembrane protein 143, TMEM143

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## TMEM143 Antibody (Center) Blocking Peptide - Protein Information

Name TMEM143

**Cellular Location** 

Membrane; Multi-pass membrane protein

## TMEM143 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

# Blocking Peptides

TMEM143 Antibody (Center) Blocking Peptide - Images

### TMEM143 Antibody (Center) Blocking Peptide - Background

TMEM143 (transmembrane protein 143) is a 459 amino acid protein encoded by a gene mapping to human chromosome 19. Consisting of around 63 million bases with over 1,400 genes, chromosome 19 makes up over 2% of human genomic DNA. Chromosome 19 includes a diversity of interesting genes and is recognized for having the greatest gene density of the human chromosomes. It is the genetic home for a number of immunoglobulin superfamily members including the killer cell and







leukocyte Ig-like receptors, a number of ICAMs, the CEACAM and PSG family, and Fc? receptors. Key genes for eye color and hair color also map to chromosome 19. Peutz-leghers syndrome, spinocerebellar ataxia type 6, the stroke disorder CADASIL, hypercholesterolemia and insulin-dependent diabetes have been linked to chromosome 19. Translocations with chromosome 19 and chromosome 14 can be seen in some lymphoproliferative disorders and typically involve the proto-oncogene BCL3.

# TMEM143 Antibody (Center) Blocking Peptide - References

Bailey, S.D., et al. Diabetes Care (2010) In press: Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)Simpson, J.C., et al. EMBO Rep. 1(3):287-292(2000)